Delafloxacin Meglumine: A Powerful Antibiotic for Bacterial Infections
Discover the broad-spectrum efficacy of Delafloxacin Meglumine against challenging bacterial infections.
Get a Quote & SampleProduct Core Value
Delafloxacin Meglumine
Delafloxacin Meglumine stands out as a critical pharmaceutical chemical, offering a robust solution for combating various bacterial infections. Its unique fluoroquinolone structure provides broad-spectrum antibacterial activity, making it a valuable agent in treating conditions like acute bacterial skin and skin structure infections (ABSSSI). The compound's ability to target key bacterial enzymes, DNA gyrase and topoisomerase IV, is central to its effectiveness in inhibiting bacterial DNA replication and repair.
- A Key Pharmaceutical Chemical for Modern Medicine: Delafloxacin meglumine is a vital component in the fight against bacterial pathogens, offering a reliable treatment option for ABSSSI.
- Targeting Resistance: This medication demonstrates potent activity against methicillin-resistant Staphylococcus aureus (MRSA), a significant challenge in healthcare settings.
- Mechanism of Action: It functions by inhibiting essential bacterial enzymes, DNA gyrase and topoisomerase IV, thereby disrupting bacterial DNA replication and repair processes.
- Versatile Administration: Delafloxacin Meglumine can be administered through both oral and intravenous routes, providing flexibility for patient treatment plans.
Advantages of Delafloxacin Meglumine
Broad-Spectrum Efficacy
The broad-spectrum antibacterial activity of Delafloxacin Meglumine makes it effective against a wide range of Gram-positive and Gram-negative bacteria, including difficult-to-treat strains like MRSA.
Enhanced Activity in Acidic Environments
Its anionic character allows for increased accumulation in bacteria and cells at acidic pH, enhancing its potency for intracellular infections and biofilms.
Proven Safety Profile
While offering potent antibacterial action, Delafloxacin Meglumine is noted for its generally good tolerance and low toxicity to liver and kidney functions, based on clinical studies.
Key Applications
Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Delafloxacin Meglumine is FDA-approved for the treatment of ABSSSI, providing a crucial therapeutic option for these common yet serious infections.
Community-Acquired Pneumonia (CAP)
The antibiotic is also evaluated for its efficacy in treating community-acquired pneumonia, demonstrating its versatility in addressing respiratory tract infections.
Targeted Bacterial Therapies
As a potent fluoroquinolone, it is a key player in targeted bacterial therapies, especially when dealing with infections caused by susceptible bacteria.
Antimicrobial Research and Development
Delafloxacin Meglumine serves as a vital reference standard and research tool in the development of new antibacterial agents and analytical methods.